European Commission approve burosumab (Crysvita) for use in older adolescents and adults with X-linked hypophosphataemia
Approval was based on studies which found that treatment with burosumab increased and maintained serum phosphate levels in the normal range, helped to heal pseudofractures and fractures related to osteomalacia and improved osteomalacia.
Source:
PharmaTimes
SPS commentary:
Approval was based on studies which found that treatment with burosumab increased and maintained serum phosphate levels in the normal range, helped to heal pseudofractures and fractures related to osteomalacia and improved osteomalacia.